PT - JOURNAL ARTICLE AU - Carlos Juri AU - Pedro Chaná-Cuevas AU - Vasko Kramer AU - Rosemarie Fritsch AU - Claudia Ornstein AU - Analía Cuiza AU - Carlos Hernández AU - Katiuska Villanueva AU - Teresa Cordova AU - Jorge Mauro AU - Adrian Ocampo AU - Boris Rebolledo-Jaramillo AU - Gonzalo Encina AU - Andrea Calleja AU - Javiera Dinator AU - Juan Pablo Alcayaga AU - Nicolas A. Crossley AU - Gabriela M. Repetto TI - Prodromal manifestations of Parkinson’s disease in adults with 22q11.2 microdeletion syndrome AID - 10.1101/2022.05.18.22275282 DP - 2022 Jan 01 TA - medRxiv PG - 2022.05.18.22275282 4099 - http://medrxiv.org/content/early/2022/05/20/2022.05.18.22275282.short 4100 - http://medrxiv.org/content/early/2022/05/20/2022.05.18.22275282.full AB - 22q11.2 microdeletion syndrome (22qDS) was recently identified as a risk factor for development of early-onset Parkinson’s disease (PD). The classical motor manifestations of this disease are preceded by early signs and symptoms of neurodegeneration. The progression of 22qDS-associated PD is unknown. We aimed to evaluate the presence of prodromal PD in a group of adults with 22qDS using the Movement Disorders Society (MDS) Criteria for Prodromal PD. Thirty-eight persons with 22qDS and 13 age-matched controls participated in the study, and their results were compared using the Mann-Whitney U test. Persons with 22qDS had lower scores on olfaction testing (p=7.42E×10−5), higher scores on the COMPASS 31 scale for dysautonomia (p=2.28×10−3) and on the motor evaluation using Movement Disorder Society (MDS)-sponsored revision of Unified Parkinson’s Disease Rating Scale motor subscore (UPDRS-III) (p=1.84×10−4), compared with healthy controls. Home polysomnogram did not find participants with REM-sleep behavior disorder. Integrity of nigrostriatal dopaminergic system was evaluated by PET-CT imaging of presynaptic dopamine with 18F-PR04.MZ. Patients showed significantly higher specific binding ratios in the striatum, compared to controls (p=9.57×10−3 at the caudate nuclei). Two patients with 22qDS (5.2%) had decreased uptake in the posterior putamen (less than 60% of controls) and one fulfilled MDS criteria for prodromal PD. These results show that patients with 22qDS manifest some signs and symptoms of prodromal PD such as hyposmia, dysautonomia and mild movement alterations. In the majority, this was associated with elevated dopaminergic signaling, suggesting that loss of dopaminergic neurons may not be the cause. A smaller subgroup did show evidence of a decrease in nigrostriatal dopaminergic signaling, as seen in classical prodromal PD. Longitudinal studies are necessary to understand the progression to and risk of PD in persons with 22qDS.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was funded by Fondecyt grants 1171014 and 1211411, Fondequip EQM 150093, ACT 192064 (ANID-Chile)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics Committee of Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Santiago, Chile, gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors